Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amin Elashker

Internal Medicine Danbury, CT Doctor of Osteopathy

NPI 1093794182 CMS profile 821341

100 Reserve Rd Ste A4, Danbury, CT 06810

Open in the dashboard

General payments

$5,828

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amin Elashker of Danbury, CT is reported in the CMS Open Payments database as having received $5,828 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $875 45
2024 General $663 35
2023 General $1,334 68
2022 General $1,355 74
2021 General $994 56
2020 General $497 28
2019 General $110 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amin Elashker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Amin Elashker were reported at $875. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Amin Elashker Internal Medicine median Middle half National median
2019 $110 $159 $48–$570 $163
2020 $497 $119 $33–$402 $114
2021 $994 $135 $37–$521 $132
2022 $1,355 $141 $42–$496 $149
2023 $1,334 $149 $45–$519 $160
2024 $663 $154 $47–$537 $164
2025 $875 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $888 41 payments
  2. Novo Nordisk Inc $694 39 payments
  3. GlaxoSmithKline, LLC. $497 25 payments
  4. AstraZeneca Pharmaceuticals LP $471 29 payments
  5. Pfizer Inc. $467 26 payments
  6. Lilly USA, LLC $465 26 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $241 13 payments
  8. Janssen Pharmaceuticals, Inc $235 12 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $174 9 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $151 9 payments
  11. Other $1,543 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,828 313 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $379 18 payments
  2. MOUNJARO $367 21 payments
  3. Ozempic $339 20 payments
  4. RYBELSUS $339 20 payments
  5. FARXIGA $329 20 payments
  6. VRAYLAR $291 15 payments
  7. XIFAXAN $241 13 payments
  8. XARELTO $235 12 payments
  9. QULIPTA $234 8 payments
  10. NURTEC ODT $217 13 payments
  11. Other $4,548 249 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

3,789

Median for Internal Medicine: 777

Drug cost

$280,901

Median for Internal Medicine: $73,373

Branded share of claims

15.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 65 $58,748
Jardiance Empagliflozin Brand 37 $44,196
Ozempic Semaglutide Brand 27 $29,251
Farxiga Dapagliflozin Propanediol Brand 21 $28,062
Januvia Sitagliptin Phosphate Brand 25 $23,535
Trulicity Dulaglutide Brand 14 $23,227
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $20,558
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $9,670
Breo Ellipta Fluticasone/Vilanterol Brand 14 $6,925
Atorvastatin Calcium Generic 240 $2,446

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$83,918

Of which drugs: $2,392

Medicare patients

373

Average age 74

Services billed

1,925

181 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 40%
Diabetes 28%
Ischemic heart disease 23%
Chronic kidney disease 17%
Depression 17%
Atrial fibrillation 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $95
$95 — —
QULIPTA
  • AbbVie, Inc. $64
$64 — —
Veozah
  • Astellas Pharma US Inc $43
$43 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $39
$39 34 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record